NetScientific Appoints Dr François R. Martelet As Chief Executive Officer

London, UK – 11 May 2015 – NetScientific (AIM: NSCI), the biomedical and healthcare technology group, announces the appointment of Dr François R. Martelet as Chief Executive Officer and Board Director.

Dr Martelet will join the Group on 8 June 2015. Sir Richard Sykes, who has been Executive Chairman prior to this appointment, will revert to his position as Non-Executive Chairman.

Most recently, Dr Martelet has served as senior advisor to the CEO and Interim SVP at Stallergenes SA where he was responsible for international commercial strategies. During this period, sales revenues grew by 20+% and various new products were launched, including Oralair®, into ex-US markets. Before this, he was CEO at Topotarget A/S, a publicly traded European biotech company specialised in oncology therapeutics which he successfully transformed from a research based organisation into a late-stage clinical development company ready for a European exit.

Prior to this, Dr Martelet served as CEO of Avax Technologies Inc., a US biotech company specialised in therapeutic oncology vaccines. He has also held senior level commercial positions at Merck & Co, Inc. (VP & Global Franchise Head-Oncology), Novartis Pharma (SVP & Head of Central & Eastern Europe, Middle East and Africa), Schering-Plough and Eli Lilly.

Sir Richard Sykes, Chairman of NetScientific, commented: "Dr Martelet further strengthens NetScientific's management team at a time when a number of the Group's portfolio companies will soon be entering commercialisation. He brings over 20 years of biopharma experience and a proven track record of shaping and developing businesses to deliver returns. With his broad experience in both large and small companies, deep knowledge of commercialisation and his proven managerial capability, François will be a great asset to the business in growing its innovative technology portfolio." Dr Martelet said: "It is a great opportunity to take on the CEO role at NetScientific, working with the Board and the management team in the transformation process of its portfolio companies. I am particularly pleased to work with Sir Richard, whose track record in the Pharmaceutical and Biotechnology fields is very impressive. I look forward to being able to shape the direction of NetScientific's portfolio of game-changing healthcare platform technologies."

François Regis Martelet, aged 55 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships
Pharmaexcellentia SA
(personal service company)

Past Directorships
Avax Technologies Inc.
Ennovance Capital LLC
European BioPharmaceutical Enterprises

There is no further information to be disclosed under Schedule Two paragraph (g) of the AIM Rules for Companies.

- ENDS -

Notes To Editors

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.NetScientific.net Issued for and on behalf of NetScientific by Instinctif Partners.

For more information please contact:
NetScientific
Peter Thoms, CFO
Tel: +44 (0)77 2055 5752

Investec
Gary Clarence / Daniel Adams
Tel: +44 (0)20 7597 4000
Instinctif Partners
Melanie Toyne-Sewell / Jayne Crook
Tel: +44 (0)20 7457 2020
Email: [email protected]
 

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.